|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:ageRange
|
65-79 years
|
|
gptkbp:announced
|
2015
|
|
gptkbp:controls
|
placebo
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:designer
|
gptkb:clinical_trial
|
|
gptkbp:diseasesStudied
|
gptkb:cancer
gptkb:cardiovascular_disease
gptkb:dementia
gptkb:type_2_diabetes
|
|
gptkbp:duration
|
6 years (planned)
|
|
gptkbp:focusesOn
|
gptkb:metformin
|
|
gptkbp:fullName
|
Targeting Aging with Metformin trial
|
|
gptkbp:goal
|
to test whether metformin can delay the onset of age-related diseases
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TAME trial
|
|
gptkbp:intervention
|
gptkb:metformin
|
|
gptkbp:participants
|
3000 (planned)
|
|
gptkbp:principalInvestigator
|
gptkb:Nir_Barzilai
|
|
gptkbp:result
|
time to occurrence of age-related chronic diseases
|
|
gptkbp:significance
|
first major trial to test a drug for aging itself
|
|
gptkbp:sponsor
|
gptkb:American_Federation_for_Aging_Research
|
|
gptkbp:status
|
planned
|
|
gptkbp:studies
|
aging
healthspan
|
|
gptkbp:targetAudience
|
older adults
|
|
gptkbp:bfsParent
|
gptkb:Nir_Barzilai
|
|
gptkbp:bfsLayer
|
7
|